MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY
The invention relates to a compound of formula (I): wherein: ALK is a (C 1 -C 6 )alkylene group; X 1 et X 2 are each independently one of the following groups: —CH═CH—, —CO—, —CONR—, —NRCO—, —COO—, —OCO—, —OCONR—, —NRCOO—, —NRCONR′—, —NR—, —S(O) n (n=0, 1 or 2) or —O—; R and R′ are independently H or a (C 1 -C 6 )alkyl group; i is an integer of from 1 to 40, preferably from 1 to 20, and more preferably from 1 to 10; j is an integer corresponding to 1 when X 2 is —CH═CH— and 2 when X 2 is not —CH═CH—; Z b is a simple bond, —O— or —NH— and R b is H or a (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, aryl, heteroaryl or (C 3 -C 7 )heterocycloalkyl group; or Z b is a single bond and R b is Hal.
1 . A compound of formula (I):
wherein:
ALK is a (C 1 -C 6 )alkylene group;
X 1 et X 2 are each independently one of the following groups: —CH═CH—, —CO—, —CONR—, —NRCO—, —COO—, —OCO—, —OCONR—, —NRCOO—, —NRCONR′—, —NR—, —S(O) n (n=0.1 or 2) or —O—;
R and R′ are independently H or a (C 1 -C 6 )alkyl group;
i is an integer of from 1 to 40;
j is an integer corresponding to 1 when X 2 is —CH═CH— and 2 when X 2 is not —CH═CH—;
Z b is a simple bond, —O— or —NH— and R b is H or a (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, aryl, heteroaryl or (C 3 -C 7 )heterocycloalkyl group; or Z b is a single bond and R b is Hal.
2 . A compound according to claim 1 wherein i is an integer of from 1 to 20.
3 . A compound according to claim 1 wherein i is an integer of from 1 to 10.
4 . A compound according to claim 1 wherein X 2 is —CH═CH— or —CONR—, the CO group being linked to the —X 1 -ALK-group and R being H or a (C 1 -C 6 )alkyl group.
5 . A compound according to claim 1 wherein —X 1 -ALK- is —S—CH 2 —.
6 . A compound according to claim 1 wherein i is 3, 4, 5, 6, 7, 8, 9 or 10.
7 . A compound according to claim 1 of formula (II):
8 . A compound selected among the following ones:
9 . A compound according to claim 1 wherein —COZ b R b is —COOH, —COO(C 1 -C 6 )alkyl, —COOMe, COOCH 2 CH═CH 2 ,
the group
wherein GI represent at least one inductive group NO 2 , Hal or F or
10 . A compound according to claim 1 in the form of a base or a salt or a solvate or an hydrate of said base or said salt.
11 . A process of preparation of a conjugate comprising the steps of:
(i) bringing into contact an optionally-buffered aqueous solution of an antibody with a solution of a compound according to claim 1 ;
(ii) then optionally separating the conjugate which was formed in (i) from the unreacted reagents and any aggregate which may be present in the solution.
12 . A process according to claim 11 wherein the temperature of the reaction usually varies from 20 to 40° C. and/or the reaction time varies from 1 to 24 hours.
13 . A process according to claim 11 wherein after step (i) or (ii), the conjugate-containing solution is submitted to an additional step (iii) of ultrafiltration and/or diafiltration.
14 . A process according to claim 11 wherein the antibody is an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor and comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 1, 2, and 3, and wherein said light chain comprises three sequential complementarity-determining regions having amino acid sequences represented by SEQ ID NOS: 4, 5, and 6.
15 . A process according to claim 14 wherein the antibody or the epitope-binding fragment is a humanized or resurfaced antibody or epitope-binding fragment thereof.
16 . A process according to claim 14 wherein said heavy chain comprises an amino acid sequence consisting of SEQ ID NO: 12, and wherein said light chain comprises an amino acid sequence consisting of SEQ ID NO: 14.
17 . A process according to claim 14 wherein said heavy chain consists in an amino acid sequence SEQ ID NO: 18, and wherein said light chain consists in an amino acid sequence SEQ ID NO: 16.
18 . A conjugate obtained by a process according to claim 11 .
19 . A conjugate according to claim 18 having an average DAR, measured with a UV spectrophotometer, above 4, the DAR being determined by the following equation
DAR= c D /c A
with:
c D =[(ε A280 ×A 252 )−(ε A252 ×A 280 )]/[(ε D252 ×ε A280 )−(ε A252 ×ε D280 )]
c A =[A 280 −(c D ×ε D280 )]/ε A280
ε D252 =26,159 M −1 cm −1
ε D280 =5,180 M −1 cm −1
ε A280 =224,000 M −1 cm −1
ε A252 =82,880 M −1 cm −1
A 252 and A 280 being the absorbances of the conjugate measured on the UV spectrophotometer at respectively 252 and 280 nm.
20 . A conjugate according to claim 19 wherein the DAR is between 4 and 10.
21 . A conjugate according to claim 20 wherein the DAR is between 4 and 7.
22 . A conjugate according to claim 19 wherein the DAR is between 5 and 8.
23 . A conjugate according to claim 22 wherein the DAR is between 5.5 and 8
24 . A conjugate according to claim 23 wherein the DAR is between 5.9 and 7.5.
25 . An aqueous solution comprising a conjugate according to claim 18 .
26 . A method of treating cancer in a patient in need thereof comprising administering to said patient an effective dose of a compound of claim 1 .
27 . A method of treating cancer in a patient in need thereof comprising administering to said patient an effective dose of a compound of claim 18 .
28 . A process for preparing a conjugate comprising covalently linking a compound of claim 1 to an antibody.